-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale

Reuters·03/16/2026 20:25:57

Please log in to view news